Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ether doai
Patent
1991-08-26
1993-04-20
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ether doai
514732, 568632, 568633, 568634, A61K 3108, C07C 4321, C07C 4323
Patent
active
052043738
ABSTRACT:
The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-naphthalenols of the present invention are thus useful for cholesterol/lipid lowering in cases of hypercholesterolemia, hyperlipidemia, and atherosclerosis.
REFERENCES:
patent: 4603142 (1986-07-01), Burger et al.
patent: 4680310 (1987-07-01), Hengartner et al.
patent: 4935560 (1990-06-01), Klaus et al.
Expert Panel "Report on the National Cholesterol Education Program Expert Panel on Detection, Evaluation and the Treatment of High Blood Cholesterol in Adults," Arch.Intern.Med. 148, 36-39, (1988).
Brown, et al., J. Lipid Res, 21: 505-517 (1980).
Wright, et al, A symposium On Drugs Affecting Lipid Metabolism, Houston, Tex. (Nov. 1989).
Qureshi, et al, J. Biol. Chem. 261: 10544-10550, (1986).
Qureshi, et al, Suppression of Cholesterolgenesis in Hypercholesterolemic Humans by Tocotrienols of Barley and Palm Oils, Antioxidant and Degenerative Diseases Conference, Berkeley, Calif. (Jan. 1990).
Yamaoka, et al, Yukagaku, 34: 120-122 (1985).
Santrucek, M., Krepelka, J., Drugs of the Future, 13: 973-996 (1988).
Buckley, M., Goa, K. L., Price, A. H., Brogden, R. N., Drugs, 37: 761-800 (1989).
Gwynne, J. T., Schwartz, C. J., Am. J. Cardiology, 62: 1B-77B (1988).
Bristol--Myers Squibb Company
Cintins Marianne M.
Kaye Michelle A.
Peabody John
LandOfFree
Farnesylated tetrahydro-naphthalenols as hypolipidemic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Farnesylated tetrahydro-naphthalenols as hypolipidemic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesylated tetrahydro-naphthalenols as hypolipidemic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1526488